Shenzhen New Industries Biomedical Engineering Co. Ltd (Snibe) was founded in 1995 as a professional biomedical company that specializes in R&D, production, and sales of clinical laboratory instruments and reagents kits. Since 1995, it has been focusing on the R&D of immunoassay products with more than 20 years. After decades of effort, in 2008, Snibe became the first company in China to successfully develop and release fully automated chemiluminescence immunoassay (CLIA) system. Till now, the company has established good cooperation relationship with local distributors in over 100 countries and areas with 5000 analyzer units installation. The market share is increasing gradually; the company also depends on the competitive advantages to cooperate with more customers globally.

The company adopts two important technologies: one is labeling technology which determines the reaction mode, and the other is nano-magnetic microbeads separation technology, which determines the sensitivity and precision of the reagents and is wildly used in the field of CLIA, compared with traditional separation technology with more advantages.

In the New Year, Snibe has more active marketing actions, including constantly participating in important global exhibitions, such as Arab Health, AACC, MEDICA, and professional congress in different regions. R&D group will devote to new products. New biochemistry analyzers BC240 and BC360 will be launched soon. These are compact models and are incorporated with liquid level sensor, volume tracking, solid crash protection and clog detection, and diffraction grating filters with minimum 16 standard filters in the range 340-800 nm.

With constant efforts, the company offers total solution to the laboratory - Biolumi 8000, the integrated system has four modules:

  • Immunoassay module (280 tests/hour, magnetic separation, flash CLIA technology, more than 120 parameters 25 reagents on board, clot detection, liquid level detection)
  • Biochemistry module (1600 tests/hour, continuous and automatic reagent loading during operation, clot detection, liquid level detection, wavelength range 340-800 nm, detecting 16 wavelengths simultaneously)
  • Electrolyte module (1000 tests/hour, continuous and automatic reagent loading during operation, clot detection, liquid level detection)
  • Sample processing module (280 samples loading at one time, recognizing the barcode of primary tube, continuous loading and unloading samples during operation, specific STAT channel), which has different combination mode according to customers' requirements).

In the end of 2015, Biolumi 8000 was installed successfully in India market; the assessment result shows the system is really stable and acceptable, for example, intra- and inter-precision CV is 0.7 and 1.5 percent, respectively. It has shown good result in reagent also, for example, the cross contamination rate in M4000 is less than 0.0022 percent, the correlation of 25-OH Vitamin D assay between other major providers is 0.959, and the end-user was satisfied with the assessment. The successful assessment of integrated system Biolumi 8000 demonstrates the good performance in end-users' environment, the R&D strength of Snibe. We believe after the experience of integrated system assessment, products will scale new heights in near future.

Maglumi series now has several hundred installations in all of India even in the chain labs. The distributors diversify our activities by introducing the immunology range, after doing more research and evaluation; finally distributors choose the company because of large portfolio, for goods quality results, and best after-sales service support. The company has set up the service point for Indian customers for much more convenience. In the future, the company will keep on working hard for Indian market; make it grow faster and more suitable for local customers' requirements. With 20 years of experience and focus, Snibe is confident of offering more choices for global customers. The company will offer continuous service and bring excellent products in the maqrket.

The author is Vice Director, Snibe


A New Cancer Treatment

 

Digital version